Profile photo Marianne Boes

Marianne Boes

Associate Professor

Strategic program(s):

Biography

Marianne Boes heads the pediatric immunology laboratory at the UMC Utrecht, embedded in the Center for Translational Immunology. Her team focuses on approaches for harnessing the strength of the immune response and its promise to redirection using immune response modification, as preventive or therapeutic medicine. Boes trained in the USA in immunology and cell biology research (1996-2008). She performed PhD research at Massachusetts Institute of Technology (MIT), at the Koch Institute for integrative Cancer Research under supervision of prof. Jianzhu Chen. Here she studied immunodeficiency mechanisms using mouse models. Postdoctoral work she performed at Harvard Medical School in the laboratory of prof. Hidde Ploegh.

In 2004, Dr. Boes started her independent research lab at Brigham and Women’s Hospital/Harvard Medical School, financed in part by an NWO-Veni grant in 2004 and a large NIH-RO1 grant that was awarded to her.  She is the founding chair of the Young Academy of the UMC Utrecht (chair Sept 2019-Jan 2022) and board member of the CUCo working group of the Young Academies of the Strategic Alliance between TU-Eindhoven, Wageningen, Utrecht University and UMC-Utrecht, 2019-2022. Boes serves as coordinator of the course 'Advanced Immunology' and van Kinsbergen Advanced+ Immunology for PhD students. She is current member of the I&I graduate school teaching committee and the Board of Examiners, subcommittee Assessment Support Panel (ASP) @ GSLS-life Sciences Academy. She thoroughly enjoys to meet and learn from researchers, patients and societal partners in different fields. 

Research groups

Pediatric immunology team

Research aim

The pediatric immunology team focuses on the under-explored research field of immune response modification for the prevention of immune-driven diseases. The goal of our research is to develop interventions that can prevent disease manifestations.

Go to group

Primary immunodeficiency

Research aim

To address unmet medical needs by detecting novel primary immunodeficiency, and improving clinical practice by optimizing diagnosis, prognosis and treatment of disease.

Go to group

Recent publications

Targeted inhibition of glycogen synthase kinase-3 using 9-ING-41 (elraglusib) enhances CD8 T-cell-reactivity against neuroblastoma cells A Markovska, K Somers, J Guillaume, J Melief, A P Mazar, D M Schmitt, H S Schipper, M Boes
Scientific Reports, 2024, vol. 14
Correction Jan Pačes, Valéria Grobárová, Zdeněk Zadražil, Karolina Knížková, Nikola Malinská, Liliana Tušková, Marianne Boes, Jan Černý
Current Protocols, 2024, vol. 4, p.e1050
Finding joy, creativity and meaning through unusual interdisciplinary collaborations J. Duncan, S. Knittel, S. Hofmann, F. Albronda, D. Lakens, J. P. Wijnen, M. D. Veldhuizen, D. Tetteroo, C. Schoevaars, M. Boes, S. Brugman, C. Lamain,
Humanities and Social Sciences Communications, 2024, vol. 11
Strategies to overcome low MHC-I expression in paediatric and adult tumours J Guillaume, A Perzolli, M Boes
Immunotherapy advances, 2024, vol. 4
Salivary polyreactive antibodies and Haemophilus influenzae are associated with respiratory infection severity in young children with recurrent respiratory infections. Mischa H Koenen, W A A de Steenhuijsen Piters, Marien I de Jonge, Jeroen D Langereis, Stefan Nierkens, Mei Ling J N Chu, Roosmarijn van der Woude, Robert P de Vries, Elisabeth A M Sanders, Debby Bogaert, Erhard van der Vries, Marianne Boes, Lilly M Verhagen
The European respiratory journal, 2024, vol. 64
Long-COVID-19 Marianne Boes, Pascal Falter-Braun
Signal transduction and targeted therapy, 2023, vol. 8, p.1-2